Actively Recruiting
Single and Twice-daily Dosing of Ramipril on Renal Function in Chronic Kidney Disease Patients With Reduced Ejection Fraction Heart Failure
Led by Evi Liliek Wulandari · Updated on 2025-12-10
80
Participants Needed
1
Research Sites
30 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This study compares the effects of once-daily versus twice-daily ramipril dosing on renal function in chronic kidney disease (CKD) patients with heart failure with reduced ejection fraction (HFrEF). Outcomes include changes in plasma renin activity, malondialdehyde, interleukin-6, albuminuria, and cystatin C after 30 days of therapy.
CONDITIONS
Official Title
Single and Twice-daily Dosing of Ramipril on Renal Function in Chronic Kidney Disease Patients With Reduced Ejection Fraction Heart Failure
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Female or male aged over 18 years
- Diagnosis of chronic kidney disease stage 3 to 5 not requiring dialysis
- Diagnosis of heart failure with reduced ejection fraction (ejection fraction less than 40%)
You will not qualify if you...
- Receiving hemodialysis therapy
- History of intolerance to ACE inhibitors
- Refractory hyperkalemia
- Pregnancy
- History of angioedema to ACE inhibitors
- Receiving sacubitril-valsartan therapy
- Receiving angiotensin receptor blocker therapy
- Hypotension with blood pressure less than 90/60 or patients in shock
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
UNS Hospital
Kartasura, Central Java, Indonesia
Actively Recruiting
Research Team
E
Evi L Wulandari, MD., Internist
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
TRIPLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here